Pay in 4 interest-free payments of $7.13 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
[PMID: 10508125] PubMed record related to this compound for laboratory literature review
Latin America's pharmaceutical ecosystem is strengthened by locally manufactured medicines that are critical for job creation and future health security
Key Benefits Observed in Clinical Trials Treatment of Erythropoietic Protoporphyria (EPP): MT-1 (Afamelanotide) is FDA-approved for use in patients with EPP, a rare genetic disorder that causes extreme photosensitivity, leading to severe pain and skin damage upon light exposure
The more important question is who is driving todays prescriptions, and which segments of Indias physician base still remain outside the category
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
Notably, no government drug regulatory agency across the world had approved for the use of any compound incorporating the Melanotan II peptide by 2010 Historical Development Melanotan II was first developed at the University of Arizona
US$ 28.81
US$ 27.67
US$ 28.78
US$ 20.44
US$ 22.04
US$ 26.65
